论文信息 - Transient leukocytopenia following combination therapy for COVID-19 - 字舞流文

Transient leukocytopenia following combination therapy for COVID-19

N. Inui | Yutaro Nakamura | T. Suda | Y. Inoue | M. Karayama | H. Hozumi | K. Furuhashi | T. Fujisawa | N. Enomoto | Yuzo Suzuki | A. Fukada | Hirofumi Watanabe | Yuko Tanaka | K. Oishi | M. Katsumata | Y. Endo | Kazuo Tsuchiya | Sho Takuma | Y. Nakamura | Y. Aoshima | Y. Mochizuka | Kyohei Oishi

[1] Brenda J. Crowe,et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial , 2021, The Lancet Respiratory Medicine.

[2] N. Awano,et al. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19 , 2021, Respiratory Investigation.

[3] Cameron R. Wolfe,et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, The New England journal of medicine.

[4] Luke H. Hoeppner,et al. Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability , 2020, bioRxiv.

[5] J. Kremer,et al. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib , 2020, RMD open.

[6] 道子相原,et al. 薬疹up to date , 2011 .

[7] Urso FORTE. Urso. HIGHLIGHTS OF PRESCRIBING INFORMATION , 2007 .